Zealand Pharma A/S (ZEAL.CO)
DKK 802.5
(0.44%)
DKK 802.5
(0.44%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -572.23 Million DKK | 31.27% |
| 2022 | -816.59 Million DKK | 22.24% |
| 2021 | -1.05 Billion DKK | -26.72% |
| 2020 | -828.75 Million DKK | -40.96% |
| 2019 | -587.94 Million DKK | -190.12% |
| 2018 | 652.39 Million DKK | 364.79% |
| 2017 | -246.38 Million DKK | -113.05% |
| 2016 | -115.64 Million DKK | -42.2% |
| 2015 | -81.32 Million DKK | -10.59% |
| 2014 | -73.53 Million DKK | 60.38% |
| 2013 | -185.61 Million DKK | -672.95% |
| 2012 | 32.39 Million DKK | 111.36% |
| 2011 | 15.32 Million DKK | 114.1% |
| 2010 | -108.69 Million DKK | -36.0% |
| 2009 | -79.92 Million DKK | -78.85% |
| 2008 | -44.68 Million DKK | 28.53% |
| 2007 | -62.52 Million DKK | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | -267.67 Million DKK | -4.63% |
| 2024 Q1 | -255.84 Million DKK | -5.53% |
| 2023 Q4 | -242.42 Million DKK | -635.4% |
| 2023 FY | -561.23 Million DKK | 31.27% |
| 2023 Q2 | -195.36 Million DKK | -15.82% |
| 2023 Q3 | 45.27 Million DKK | 123.18% |
| 2023 Q1 | -168.67 Million DKK | 29.25% |
| 2022 Q2 | -237.2 Million DKK | 21.46% |
| 2022 Q4 | -238.4 Million DKK | -47.1% |
| 2022 FY | -816.59 Million DKK | 22.24% |
| 2022 Q1 | -301.99 Million DKK | -5.02% |
| 2022 Q3 | -162.07 Million DKK | 31.67% |
| 2021 Q4 | -287.57 Million DKK | -35.77% |
| 2021 Q1 | -260.9 Million DKK | 23.92% |
| 2021 Q3 | -211.8 Million DKK | 26.94% |
| 2021 FY | -1.05 Billion DKK | -26.72% |
| 2021 Q2 | -289.91 Million DKK | -11.12% |
| 2020 FY | -828.75 Million DKK | -40.96% |
| 2020 Q2 | -53.71 Million DKK | 69.69% |
| 2020 Q3 | -254.89 Million DKK | -374.58% |
| 2020 Q4 | -342.94 Million DKK | -34.54% |
| 2020 Q1 | -177.2 Million DKK | 4.63% |
| 2019 Q3 | -130.06 Million DKK | 4.57% |
| 2019 Q4 | -185.8 Million DKK | -42.86% |
| 2019 FY | -587.94 Million DKK | -190.12% |
| 2019 Q1 | -135.78 Million DKK | 1.39% |
| 2019 Q2 | -136.28 Million DKK | -0.37% |
| 2018 Q2 | -131.93 Million DKK | -59.89% |
| 2018 FY | 652.39 Million DKK | 364.79% |
| 2018 Q1 | -82.51 Million DKK | 25.04% |
| 2018 Q4 | -137.69 Million DKK | -113.69% |
| 2018 Q3 | 1 Billion DKK | 862.13% |
| 2017 Q2 | -94.77 Million DKK | -2752.86% |
| 2017 FY | -246.38 Million DKK | -113.05% |
| 2017 Q3 | -38.21 Million DKK | 59.68% |
| 2017 Q4 | -110.07 Million DKK | -188.04% |
| 2017 Q1 | -3.32 Million DKK | -105.72% |
| 2016 Q4 | 58.04 Million DKK | 373.96% |
| 2016 Q1 | -64.67 Million DKK | -183.98% |
| 2016 FY | -115.64 Million DKK | -42.2% |
| 2016 Q3 | -21.18 Million DKK | 75.93% |
| 2016 Q2 | -88.01 Million DKK | -36.08% |
| 2015 Q2 | -64.56 Million DKK | -30.41% |
| 2015 FY | -81.32 Million DKK | -10.59% |
| 2015 Q1 | -49.51 Million DKK | 27.15% |
| 2015 Q4 | 77 Million DKK | 274.01% |
| 2015 Q3 | -44.25 Million DKK | 31.46% |
| 2014 Q3 | 13.93 Million DKK | 128.95% |
| 2014 Q2 | -48.11 Million DKK | -268.18% |
| 2014 Q1 | 28.6 Million DKK | 163.02% |
| 2014 FY | -73.53 Million DKK | 60.38% |
| 2014 Q4 | -67.96 Million DKK | -587.89% |
| 2013 Q3 | -34.99 Million DKK | 26.03% |
| 2013 Q2 | -47.31 Million DKK | 18.31% |
| 2013 Q1 | -57.91 Million DKK | -4.62% |
| 2013 FY | -185.61 Million DKK | -672.95% |
| 2013 Q4 | -45.39 Million DKK | -29.71% |
| 2012 Q3 | -39 Thousand DKK | -100.18% |
| 2012 FY | 32.39 Million DKK | 111.36% |
| 2012 Q4 | -55.36 Million DKK | -141848.72% |
| 2012 Q1 | 65.63 Million DKK | 421.41% |
| 2012 Q2 | 22.16 Million DKK | -66.23% |
| 2011 Q3 | -19.21 Million DKK | -120.95% |
| 2011 Q1 | -43.31 Million DKK | 31.35% |
| 2011 FY | 15.32 Million DKK | 114.1% |
| 2011 Q4 | -20.42 Million DKK | -6.26% |
| 2011 Q2 | 91.71 Million DKK | 311.74% |
| 2010 Q1 | -25.67 Million DKK | 0.0% |
| 2010 Q4 | -63.09 Million DKK | -22.8% |
| 2010 Q3 | -51.37 Million DKK | -263.38% |
| 2010 Q2 | 31.44 Million DKK | 222.49% |
| 2010 FY | -108.69 Million DKK | -36.0% |
| 2009 FY | -79.92 Million DKK | -78.85% |
| 2008 FY | -44.68 Million DKK | 28.53% |
| 2007 FY | -62.52 Million DKK | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| ALK-Abelló A/S | 666 Million DKK | 185.922% |
| Bavarian Nordic A/S | 1.49 Billion DKK | 138.212% |
| Genmab A/S | 5.32 Billion DKK | 110.754% |
| Gubra A/S | -49.41 Million DKK | -1057.978% |
| Novo Nordisk A/S | 102.57 Billion DKK | 100.558% |
| Orphazyme A/S | -27.04 Thousand DKK | -2116086.532% |
| Pharma Equity Group A/S | -25.29 Million DKK | -2162.436% |